Skip to main content

Advertisement

SpringerLink
Log in

A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Complement-dependent cytotoxicity (CDC) is a key mechanism of Rituximab (RTX) action in killing non-Hodgkin’s lymphoma (NHL) cells both in vitro and probably in vivo. A DeImmunized, mouse/human chimeric monoclonal antibody (Mab), H17, specific for cell-associated complement C3 cleavage products, C3b and iC3b, was generated to enhance RTX-mediated killing of target cells by CDC. When NHL cell lines were treated with RTX and H17 in the presence of complement for 1 h, there was 40–70% more cell death than that observed with RTX alone. The enhancing effect of H17 was also seen over longer treatment periods. H17 was tested ex vivo against primary cells from NHL and chronic lymphocytic leukemia (CLL) patients. In RTX-resistant NHL samples, H17 enhanced RTX-mediated killing; in the remaining samples RTX + complement alone promoted more than 80% killing, and no significant enhancement was observed. The H17 antibody also increased RTX-mediated killing in four out of nine CLL samples. H17 may have therapeutic applications in NHL and CLL treatment as an adjunctive therapy to RTX. It might also enhance the activity of other therapeutic antibodies that work through CDC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Boye J, Elter T, Engert A (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14:520

    Google Scholar 

  2. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754

    Google Scholar 

  3. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443

    Google Scholar 

  4. Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW, French RR, Glennie MJ (2003) Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101:1045

    Google Scholar 

  5. Cragg MS, Glennie MJ (2004) Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 103:2738

    Google Scholar 

  6. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, Botto M, Introna M, Golay J (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171:1581

    Google Scholar 

  7. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M (2003) Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40:109

    Google Scholar 

  8. Frank M, Fries L (1989) Complement. In: Paul W (ed) Fundamental Immunology. 2nd edn, Raven Press, New York, p 679

    Google Scholar 

  9. Gelderman KA, Kuppen PJ, Bruin W, Fleuren GJ, Gorter A (2002) Enhancement of the complement activating capacity of 17–1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma. Eur J Immunol 32:128

    Google Scholar 

  10. Gelderman KA, Tomlinson S, Ross GD, Gorter A (2004) Complement function in mAb-mediated cancer immunotherapy. Trends Immunol 25:158

    Google Scholar 

  11. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95:3900

    Google Scholar 

  12. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M (2001) CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98:3383

    Google Scholar 

  13. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM (1992) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863

    Google Scholar 

  14. Hainsworth JD, Litchy S, Burris HA III, Scullin DC Jr, Corso SW, Yardley DA, Morrissey L, Greco FA (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin’s lymphoma. J Clin Oncol 20:4261

    Google Scholar 

  15. Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA (2003) Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21:1746

    Google Scholar 

  16. Harjunpaa A, Junnikkala S, Meri S (2000) Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 51:634

    Google Scholar 

  17. Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS (2003) Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin’s lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 9:5866

    Google Scholar 

  18. Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, Emmerich B (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98:1326

    Google Scholar 

  19. Juhl H, Helmig F, Baltzer K, Kalthoff H, Henne-Bruns D, Kremer B (1997) Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17–1A. J Surg Oncol 64:222

    Google Scholar 

  20. Jurianz K, Maslak S, Garcia-Schuler H, Fishelson Z, Kirschfink M (1999) Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2. Immunopharmacology 42:209

    Google Scholar 

  21. Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z, Kirschfink M (1999) Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 36:929

    Google Scholar 

  22. Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, Foley PL, Taylor RP (2003) An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood 101:1071

    Google Scholar 

  23. Kennedy AD, Beum PV, Solga MD, DiLillo DJ, Lindorfer MA, Hess CE, Densmore JJ, Williams ME, Taylor RP (2004) Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 172:3280

    Google Scholar 

  24. Lindorfer MA, Jinivizian HB, Foley PL, Kennedy AD, Solga MD, Taylor RP (2003) B cell complement receptor 2 transfer reaction. J Immunol 170:3671

    Google Scholar 

  25. Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J (2003) In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101:949

    Google Scholar 

  26. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825

    Google Scholar 

  27. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP (1996) Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 149:129

    Google Scholar 

  28. Nilsson B, Nilsson UR (1985) An assessment of the extent of antigenic analogy between physiologically bound C3 and C3 denatured by sodium dodecyl sulphate. Scand J Immunol 22:703

    Google Scholar 

  29. Nilsson B, Grossberger D, Nilsson Ekdahl K, Riegert P, Becherer DJ, Nilsson UR, Lambris JD (1992) Conformational differences between surface-bound and fluid-phase complement-component-C3 fragments. Epitope mapping by cDNA expression. Biochem J 282(Pt 3):715

    Google Scholar 

  30. Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J (2001) Immunotherapy of Non-Hodgkin’s lymphomas. Hematology (Am Soc Hematol Educ Program) :221

  31. Sokoloff MH, Nardin A, Solga MD, Lindorfer MA, Sutherland WM, Bankovich AJ, Zhau HE, Chung LW, Taylor RP (2000) Targeting of cancer cells with monoclonal antibodies specific for C3b(i). Cancer Immunol Immunother 49:551

    Google Scholar 

  32. Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC (2001) Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. J Immunother 24:263

    Google Scholar 

  33. von Mehren M, Adams GP, Weiner LM (2003) Monoclonal antibody therapy for cancer. Annu Rev Med 54:343

    Google Scholar 

  34. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940

    Google Scholar 

Download references

Acknowledgements

We are grateful to Juan Li for her help in developing the Alamar Blue assay. We thank Dr. Ronald P. Taylor for his comments on the manuscript and useful discussion. We also thank Dr. Steven Jones for his comments and help on the manuscript.

Author information

Authors and Affiliations

  1. Elusys Therapeutics, 25 Riverside Drive, PO Box 102, Pine Brook, NJ, 07058, USA

    Wu Peng, Wu Peng, Xin Zhang, Nehal Mohamed, Linda L. Nardone, Steve E. Pincus, Leslie S. Casey & George L. Spitalny

  2. Department of Pathology, New York University, New York, NY, USA

    Giorgio Inghirami

  3. Hematology Division, Department of Medicine, New York University School of Medicine, New York, NY, USA

    Kenichi Takeshita

  4. The Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

    Andrew Pecora

Authors
  1. Wu Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nehal Mohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giorgio Inghirami
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenichi Takeshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrew Pecora
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Linda L. Nardone
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Steve E. Pincus
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Leslie S. Casey
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. George L. Spitalny
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wu Peng.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peng, W., Zhang, X., Mohamed, N. et al. A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation. Cancer Immunol Immunother 54, 1172–1179 (2005). https://doi.org/10.1007/s00262-005-0686-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-005-0686-1

Keywords

Search

Navigation